01
T-cell maturation
The thymus provides theenvironment where immaturelymphocytes mature intofunctional T cells.
The science
The thymus is centralto T-cell development
T-Booster explores whether a carefully designed nutritional formulation can support measurable aspects of thymus function and healthy immune ageing.
Thymus biologyT-cell development, selectionand immune diversity.
Healthy ageingAge-related decline inthymic activity.
Measured outcomesTREC DNA, blood analysisand questionnaires.
Responsible claimsSupportive nutrition,not a treatment claim.
Thymus biology
Where new T cells learnto recognise the world
The thymus is a specialised immune organ sitting behind the breastbone. Bone-marrow-derived progenitor cells travel to the thymus, where they undergo a carefully staged education: proliferation, receptor rearrangement, and rigorous positive and negative selection. Only cells that pass this process leave the thymus as functional, self-tolerant T cells, ready to help the body recognise infection and abnormal cells while limiting the risk of autoimmunity.
02
T-cell selection
Developing T cells areselected to recognise threatswhile reducing harmfulself-reactivity.
03
Immune diversity
A varied T-cell repertoiresupports responses to manypathogens and abnormalcells.
Healthy immune ageing
Thymic activityacross the lifespan
Thymic activity is strongest in early life, when the organ supports the greatest production of new T cells. From adolescence onward, functional thymic tissue gradually reduces and is increasingly replaced by fatty tissue.
01
Early life
High thymic activity supports the development and selection of a broad, responsive T-cell population.
02
Adolescence onward
Thymic involution progresses naturally, reducing the rate at which newly produced T cells enter circulation.
03
Later adulthood
Lower output contributes to age-related changes in immune diversity and response, making the thymus an important healthy-ageing research focus.
The formulation approach
A structured combinationbeyond one ingredient
T-Booster was developed through a 16-month programme involving 13 researchers. Rather than promoting a single “hero” ingredient, the team reviewed published human and mechanistic evidence for a wide range of vitamins, minerals and nutraceuticals with plausible relevance to thymic and wider immune function, then used AI-assisted literature triage alongside expert judgement to narrow the list to 18 components that could be combined safely, at practical doses, in one capsule.
01
Biological relevance
Ingredients were considered in relation to immune-cell development, metabolism, micronutrient sufficiency and oxidative balance.
02
Complementary roles
The formulation combines nutrients and nutraceuticals intended to support connected biological processes.
03
Safety and manufacturability
Selection considered established supplement use, dose practicality, compatibility and UK GMP manufacture.
04
Designed for evaluation
The programme was built around measurable human outcomes rather than marketing claims alone.
Research architecture
How the scientific storyconnects
Biological rationale, product development, human evaluation and commercial preparation are linked in one stage-gated pathway.
Biology
Thymus science
A clear biological focussupports differentiatedscientific positioning.
Formulation
18-component product
Practical, scalable andcompatible with supplementmanufacturing.
Evidence
Clinical programme
Intervention and placebocompared through DNA, bloodand questionnaire measures.
Translation
Commercial readiness
Manufacturing, brand andpartnership work progresswith the final analysis.
Scientific interpretation
What the evidence canand cannot establish
FINAL ANALYSIS PENDINGPUBLICATION IN PREPARATIONSUPPLEMENT POSITIONINGNO DISEASE CLAIMS
Preliminary findings are not final clinical claims. Full statistics, group comparison, publication and peer review remain important. Nutritional ingredients are often marketed on theoretical or mechanistic grounds alone; T-Booster’s 260-volunteer human study was designed to test the combined formulation directly in people, using TREC DNA, CBC blood markers and questionnaire-reported outcomes alongside a placebo comparison, because a plausible mechanism is not the same as a demonstrated effect.
Responsible evidence statement. Initial signals do not prove disease prevention, treatment, reversal of ageing or guaranteed clinical benefit.